Feedback
Settings

Settings

Goto Application

7,611 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12Q AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 762
1.WO/2022/167675MOLECULES FOR USE IN THE TREATMENT AND/OR PREVENTION OF COVID-19
WO - 11.08.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
 Appl.No PCT/EP2022/052944 Applicant HUMANITAS MIRASOLE S.P.A. Inventor MANTOVANI, Alberto
The present invention relates to a molecule for use in the treatment and/or prevention of viral infections caused by highly pathogenic coronaviruses, including Severe Acute Respiratory syndrome Coronavirus 2 (SARS-CoV-2), or variants thereof, Severe Acute Respiratory syndrome Coronavirus ((SARS)-CoV) and sarbecoviruses, said molecule being a mannose binding lectin (MBL) polypeptide, or a functional fragment, derivative, mutein or variant thereof, or an homologue having a percentage of identity with MBL polypeptide of at least 50, 60, 70, 80 or 90%, preferably for use in the treatment and/or prevention of 2019 Coronavirus disease (COVID-19).
2.WO/2021/178534CDI ENHANCED COVID-19 TEST
WO - 10.09.2021
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
 Appl.No PCT/US2021/020664 Applicant HACKENSACK MERIDIAN HEALTH, INC. Inventor ZHAO, Yanan
A detection panel for the universal detection of SARS-like corona viruses and SARS-CoV-2 viruses and a method for using the detection panel are provided. The detection panel may be known as a Center for Discovery and Innovation ("CDI") detection panel (CDI Enhanced COVID-19 Test) and may also include an additional primer/probe set in the detection panel to detect the human RNase P gene (RP) in control samples and clinical specimens. The detection panel is designed for both universal detection of SARS-like coronaviruses using an E gene (envelope) detection assay, and specific detection of the SARS-CoV-2, using an N2 (nucleocapsid) detection assay.
3.WO/2022/003188RAPID DETECTION KIT FOR HUMAN PATHOGENIC CORONAVIRUSES : BETACORONAVIRUS GROUP B/C AND SARS-COV-2
WO - 06.01.2022
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
 Appl.No PCT/EP2021/068409 Applicant INSTITUT PASTEUR Inventor VANHOMWEGEN, Jessica
The invention relates to reagents and methods for the rapid detection of the presence and/or absence of SARS-CoV-2 or other betacoronavirus group B/C nucleic acid in a sample and their use for the diagnosis of an infection or the detection of an environmental contamination by SARS-CoV-2 or other betacoronavirus group B/C.
4.3913069METHOD AND DIAGNOSTIC KIT FOR MULTIPLE DETECTION OF VIRUSES OF THE FAMILY CORONAVIRIDAE: SARS-COV-2, SARS-COV, HCOV AND MERS-COV
EP - 24.11.2021
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
 Appl.No 20197796 Applicant UNIV DEGLI STUDI DI BARI ALDO MORO Inventor INCHINGOLO FRANCESCO
The invention relates to a diagnostic kit for multiple detection of 4 viruses of the Family Coronaviridae: HCoV, SARS-CoV, MERS-CoV and the SARS-CoV-2 viral strain that has caused a pandemic of the disease known as COVID-19. The kit uses a "One-Step" approach with quantitative gene amplification after backward transcription of the viral genome (rRT-PCR).In order to avoid potential false negatives, the invention contains a double control using Porcine Epidemic Diarrhoea Virus (PEDV -CoV) and Ribonuclease P (RNase P-RP).
5.20230131612METHODS FOR DETECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
US - 27.04.2023
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
 Appl.No 17895848 Applicant Avellino Lab USA, Inc. Inventor Jun-Heok JANG

Methods and reagents for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) are described. Also described are methods and reagents for multiplexed detection of SARS-CoV 2 and methods and reagents for high-throughput detection of SARS-CoV 2.

6.WO/2021/173310METHODS FOR DETECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
WO - 02.09.2021
Int.Class C12Q 1/6851
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6844Nucleic acid amplification reactions
6851Quantitative amplification
 Appl.No PCT/US2021/016245 Applicant AVELLINO LAB USA, INC. Inventor CHAO-SHERN, Connie
Methods and reagents for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) are described. Also described are methods and reagents for multiplexed detection of SARS-CoV 2 and methods and reagents for high-throughput detection of SARS-CoV 2.
7.WO/2021/180631COMPOSITIONS AND METHODS FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2), INFLUENZA A AND INFLUENZA B
WO - 16.09.2021
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
 Appl.No PCT/EP2021/055748 Applicant F. HOFFMANN-LA ROCHE AG Inventor FONTECHA, Marcel, R.
Methods for the rapid detection of the presence or absence of SARS-CoV-2, influenza A and influenza B in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting SARS-CoV-2, influenza A, and influenza B and kits are provided that are designed for the detection of SARS-CoV-2, influenza A and influenza B.
8.560328Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
NZ - 28.05.2010
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No 560328 Applicant New York Blood Center Inventor Jiang, Shibo
Patent 560328 Provided is an isolated neutralizing monoclonal antibody capable of binding to the receptor binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) wherein the antibody is produced by Hybridoma 30F9 with ATCC Accession No. PTA6523.
9.1020220057319PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION COMPRISING INHIBITOR AGAINST PAPAIN-LIKE PROTEASE, AND METHOD FOR SCREENING INHIBITOR
KR - 09.05.2022
Int.Class A61K 31/714
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7135Compounds containing heavy metals
714Cobalamins, e.g. cyanocobalamin, vitamin B12
 Appl.No 1020200142452 Applicant 주식회사 옵티팜 Inventor KIM JUNG HWAN
The present invention relates to: a pharmaceutical composition for preventing or treating infectious diseases caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising a papain-like protease inhibitor as an active ingredient; and to a method for screening the inhibitor. More specifically, the present invention provides: a pharmaceutical composition for preventing or treating infectious diseases caused by SARS-CoV-2 containing, as an active ingredient, an inhibitor for inhibiting the expression or activity of papain-like protease (PLpro); a food composition for preventing or ameliorating the SARS-CoV-2 infectious diseases; a composition for inhibiting SARS-CoV-2 activity; a method for screening a substance for preventing or treating SARS-CoV-2; a method for preparing a library of a substance for preventing or treating SARS-CoV-2; a library of a substance for preventing or treating SARS-CoV-2, which is prepared according to the method; and a pharmaceutical composition for preventing or treating the SARS-CoV-2 infectious diseases containing, as an active ingredient, one or more substances selected from the library. According to the present invention, compounds selected as inhibitors having SARS-CoV-2 PLpro inhibitory effects exhibit excellent antiviral effects, and thus can be effectively used in the prevention and treatment of infection caused by SARS-CoV-2. COPYRIGHT KIPO 2023
10.20150275183Human Betacoronavirus lineage C and identification of N-terminal dipeptidyl peptidase as its virus receptor
US - 01.10.2015
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No 14430010 Applicant Erasmus University Medical Center Rotterdam Inventor Bartholomeus Leonardus Haagmans

The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus classifiable as belonging to the Order: Nidovirales; Family: Coronaviridae; Subfamily: Coronavirinae; Genus: Betacoronavirus; and non-Lineage A, non-Lineage B or non-Lineage D, human betacoronavirus. The invention also provides a human virus having a receptor binding domain (RBD) capable of binding to a dipeptidyl peptidase 4. The invention also provides diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans.

# -